These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28095307)

  • 1. Pre-exposure prophylaxis and antiretroviral treatment interventions with drug resistance.
    Afassinou K; Chirove F; Govinder KS
    Math Biosci; 2017 Mar; 285():92-101. PubMed ID: 28095307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York.
    Kessler J; Myers JE; Nucifora KA; Mensah N; Toohey C; Khademi A; Cutler B; Braithwaite S
    AIDS; 2014 Nov; 28(18):2683-91. PubMed ID: 25493594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database.
    Rossotti R; Borghi V; Callegaro AP; Micheli V; Bruzzone B; Colao G; Gismondo MR; Vicenti I; Penco G; Zazzi M; Rusconi S
    J Clin Virol; 2016 Oct; 83():48-53. PubMed ID: 27591555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.
    Abbas UL; Glaubius R; Mubayi A; Hood G; Mellors JW
    J Infect Dis; 2013 Jul; 208(2):224-34. PubMed ID: 23570850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of vaginal microbiome communities on HIV antiretroviral-based pre-exposure prophylaxis (PrEP) drug metabolism.
    Cheu RK; Gustin AT; Lee C; Schifanella L; Miller CJ; Ha A; Kim C; Rodriguez VJ; Fischl M; Burgener AD; Arnold KB; Alcaide ML; Klatt NR
    PLoS Pathog; 2020 Dec; 16(12):e1009024. PubMed ID: 33270801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximizing the benefits of ART and PrEP in resource-limited settings.
    Akudibillah G; Pandey A; Medlock J
    Epidemiol Infect; 2017 Apr; 145(5):942-956. PubMed ID: 28031062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review.
    Hankins CA; Dybul MR
    Curr Opin HIV AIDS; 2013 Jan; 8(1):50-8. PubMed ID: 23201856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans.
    Spinner CD; Boesecke C; Zink A; Jessen H; Stellbrink HJ; Rockstroh JK; Esser S
    Infection; 2016 Apr; 44(2):151-8. PubMed ID: 26471511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis.
    Duwal S; Dickinson L; Khoo S; von Kleist M
    PLoS Comput Biol; 2019 Jan; 15(1):e1006740. PubMed ID: 30699105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV pre-exposure prophylaxis (PrEP).
    Tumarkin E; Siedner MJ; Bogoch II
    BMJ; 2019 Jan; 364():k4681. PubMed ID: 30655299
    [No Abstract]   [Full Text] [Related]  

  • 12. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
    Özdener AE; Park TE; Kalabalik J; Gupta R
    Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attitudes towards new HIV biomedical prevention technologies among a cohort of HIV-negative gay men in Sydney, Australia.
    Poynten IM; Jin F; Prestage GP; Kaldor JM; Imrie J; Grulich AE
    HIV Med; 2010 Apr; 11(4):282-8. PubMed ID: 20015220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Transition From Postexposure Prophylaxis to Preexposure Prophylaxis: An Emerging Opportunity for Biobehavioral HIV Prevention.
    Jain S; Krakower DS; Mayer KH
    Clin Infect Dis; 2015 Jun; 60 Suppl 3(Suppl 3):S200-4. PubMed ID: 25972505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic.
    Rivera CG; Zeuli JD; Smith BL; Johnson TM; Bhatia R; Otto AO; Temesgen Z
    Drugs; 2023 Dec; 83(18):1677-1698. PubMed ID: 38079092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining biomedical preventions for HIV: Vaccines with pre-exposure prophylaxis, microbicides or other HIV preventions.
    McNicholl JM
    Hum Vaccin Immunother; 2016 Dec; 12(12):3202-3211. PubMed ID: 27679928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparing for pre-exposure prophylaxis: perceptions and readiness of Canadian pharmacists for the implementation of HIV pre-exposure prophylaxis.
    Yoong D; Naccarato M; Sharma M; Wilton J; Senn H; Tan DH
    Int J STD AIDS; 2016 Jul; 27(8):608-16. PubMed ID: 26025254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
    Weis JF; Baeten JM; McCoy CO; Warth C; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Mugo N; Matsen FA; Celum C; Lehman DA;
    AIDS; 2016 Jan; 30(1):31-5. PubMed ID: 26731753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Merging care and prevention: preventive properties of antiretroviral drugs and HIV chronification in the case of Switzerland.
    Genre N; Panese F
    Anthropol Med; 2022 Mar; 29(1):14-28. PubMed ID: 34544292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP).
    Abbas UL; Hood G; Wetzel AW; Mellors JW
    PLoS One; 2011 Apr; 6(4):e18165. PubMed ID: 21525976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.